Genocea Provides Fourth Quarter 2019 Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Genocea Biosciences (GNCA) Tops Q4 EPS by 5c
February 13, 2020 7:19 AM ESTGenocea Biosciences (NASDAQ: GNCA) reported Q4 EPS of ($0.34), $0.05 better than the analyst estimate of ($0.39).
Genocea made critical scientific and clinical progress in the last quarter, said Chip Clark, President and Chief Executive Officer, Genocea. The discovery and understanding of inhibigens has the potential to... More
